1. [Immunotherapy for head and neck tumors : Updates from the 2024 ASCO Annual Meeting].
- Author
-
von Witzleben A, Doescher J, Hoffmann TK, and Laban S
- Subjects
- Humans, Cancer Vaccines therapeutic use, Evidence-Based Medicine, Germany, Medical Oncology trends, Medical Oncology methods, Otolaryngology trends, Otolaryngology methods, Squamous Cell Carcinoma of Head and Neck therapy, Squamous Cell Carcinoma of Head and Neck immunology, Treatment Outcome, Head and Neck Neoplasms therapy, Head and Neck Neoplasms immunology, Immunotherapy methods, Immunotherapy trends
- Abstract
Immunotherapeutic approaches are now established in the treatment of various tumor entities, including head and neck squamous cell carcinoma (HNSCC). PD‑1 antibodies are currently approved for HNSCC with palliative intent but are increasingly being investigated in studies with curative objectives, e.g., as neoadjuvant therapy. At ASCO 2024, particular focus was placed on combinations of immunotherapy with therapeutic vaccines for human papillomavirus (HPV)-induced tumors. Moreover, the question of which patients benefit most from immunotherapy remains unresolved. The growing significance of PD-L1 expression, measured by the combined positive score (CPS), is becoming increasingly evident. This article summarizes the latest relevant findings from the largest international cancer congress, the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting., Competing Interests: Einhaltung ethischer Richtlinien Interessenkonflikt J. Doescher: Advisory Board MSD, Merck Serono. T.K. Hoffmann: Advisory Board BMS, MSD, Sanofi. S. Laban: Advisory Board BMS, MSD, Astra Zeneca, Boehringer Ingelheim, Glaxo Smith Kline. A. von Witzleben gibt an, dass kein Interessenkonflikt besteht.Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF